Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Share Facebook Twitter LinkedIn Pinterest Email Nikkei rises as Trump claims 'big progress' in direct trade talks with Japan
Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)March 26, 2026
Modiv Industrial outlines accelerated asset recycling, targets 100% manufacturing portfolio within 24 months (NYSE:MDV)March 26, 2026
By Press Room
By Press Room
By Press Room
